Biomarker Research (Sep 2020)

Redox signaling and Alzheimer’s disease: from pathomechanism insights to biomarker discovery and therapy strategy

  • Yuan-Yuan Chen,
  • Min-Chang Wang,
  • Yan-Ni Wang,
  • He-He Hu,
  • Qing-Quan Liu,
  • Hai-Jing Liu,
  • Ying-Yong Zhao

DOI
https://doi.org/10.1186/s40364-020-00218-z
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Aging and average life expectancy have been increasing at a rapid rate, while there is an exponential risk to suffer from brain-related frailties and neurodegenerative diseases as the population ages. Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide with a projected expectation to blossom into the major challenge in elders and the cases are forecasted to increase about 3-fold in the next 40 years. Considering the etiological factors of AD are too complex to be completely understood, there is almost no effective cure to date, suggesting deeper pathomechanism insights are urgently needed. Metabolites are able to reflect the dynamic processes that are in progress or have happened, and metabolomic may therefore provide a more cost-effective and productive route to disease intervention, especially in the arena for pathomechanism exploration and new biomarker identification. In this review, we primarily focused on how redox signaling was involved in AD-related pathologies and the association between redox signaling and altered metabolic pathways. Moreover, we also expatiated the main redox signaling-associated mechanisms and their cross-talk that may be amenable to mechanism-based therapies. Five natural products with promising efficacy on AD inhibition and the benefit of AD intervention on its complications were highlighted as well. Graphical Abstract

Keywords